Vidhi M Shah

Dr. Vidhi M Shah

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VSVidhi M Shah
Vidhi M Shah
SRSyed Rizvi
Syed Rizvi
ASAlexander Charles Smith
Alexander Charles Smith
MTMotoyuki Tsuda
Motoyuki Tsuda
MKMadeline Krieger
Madeline Krieger
RSRosalie C. Sears
Rosalie C. Sears
Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. However, concerns over its toxicity have hampered juglone’s clinical application. To address this issue, we have explored the use of polymeric micelles as a delivery system for juglone in pancreatic cancer treatment. These micelles, formulated using Poloxamer 407 and D-α-Tocopherol polyethylene glycol 1000 succinate, offer an innovative solution to enhance juglone’s therapeutic potential while minimizing toxicity. In-vitro studies have demonstrated that micelle-formulated juglone (JM) effectively decreases proliferation and migration and increases apoptosis in pancreatic cancer cell lines. Importantly, in-vivo, JM exhibited no toxicity, allowing for increased dosing frequency compared to free drug administration. In mice, JM significantly reduced tumor growth in subcutaneous xenograft and orthotopic pancreatic cancer models. Beyond its direct antitumor effects, JM treatment also influenced the tumor microenvironment. In immunocompetent mice, JM increased immune cell infiltration and decreased stromal deposition and activation markers, suggesting an immunomodulatory role. To understand JM’s mechanism of action, we conducted RNA sequencing and subsequent differential expression analysis on tumors that were treated with JM. The administration of JM treatment reduced the expression levels of the oncogenic protein MYC, thereby emphasizing its potential as a focused, therapeutic intervention. In conclusion, the polymeric micelles-mediated delivery of juglone holds excellent promise in pancreatic cancer therapy. This approach offers improved drug delivery, reduced toxicity, and enhanced therapeutic efficacy.

26 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VSVidhi M Shah
Vidhi M Shah
CDCraig Dorrell
Craig Dorrell
Adel Al FateaseAdel Al Fatease
Adel Al Fatease
BABrittany Allen-Petersen
Brittany Allen-Petersen
YWYeonhee Woo
Yeonhee Woo
Adam AlaniAdam Alani
Adam Alani
Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen gradient. The study evaluates the efficacy of microfluidics formulated liposomal CPD100 (CPD100Li) in PDAC. CPD100Li were formulated with a size of 95 nm and a polydispersity index of 0.2. CPD100Li was stable for a period of 18 months when freeze-dried at a concentration of 3.55 mg/mL. CPD100 and CPD100Li confirmed selective activation at low oxygen levels in pancreatic cancer cell lines. Moreover, in 3D spheroids, CPD100Li displayed higher penetration and disruption compared to CPD100. In patient-derived 3D organoids, CPD100Li exhibited higher cell inhibition in the organoids that displayed higher expression of hypoxia-inducible factor 1 alpha (HIF1A) compared to CPD100. In the orthotopic model, the combination of CPD100Li with gemcitabine (GEM) (standard of care for PDAC) showed higher efficacy than CPD100Li alone for a period of 90 days. In summary, the evaluation of CPD100Li in multiple cellular models provides a strong foundation for its clinical application in PDAC.

18 September 2025 in Cancer Research
Verified
Journal Article
Closed access
CBChloe L. Bowman
Chloe L. Bowman
CDColin J. Daniel
Colin J. Daniel
ECEric J. Carlson
Eric J. Carlson
VSVidhi M Shah
Vidhi M Shah
AFAmy S. Farrell
Amy S. Farrell
ELEllen M. Langer
Ellen M. Langer
The prolyl isomerase PIN1 is overexpressed in cancer and contributes to cancer cell–intrinsic phenotypes, including proliferation and migration. However, PIN1 may also function in stromal cells within the tumor microenvironment. In this study, we showed that PIN1 is a critical regulator of pancreatic stellate cell (PSC) state at baseline and in response to the myofibroblast-activating factor TGFβ. Loss or inhibition of PIN1 altered the epigenetic and transcriptional responses of PSCs to TGFβ, preventing PSC differentiation to a myofibroblast state and altering expression of secreted matrix proteins and signaling molecules. Consistent with inhibition of the TGFβ response, low fibroblast PIN1 expression in mouse and human pancreatic ductal adenocarcinoma correlated with low expression of αSMA, a marker of myofibroblast activation. Decreased PIN1 expression at baseline also altered paracrine hepatocyte growth factor (HGF) signaling from fibroblasts to tumor cells. PSCs with low PIN1 expression displayed reduced expression and secretion of HGF, resulting in an attenuation of c-MET receptor phosphorylation and signaling in nearby cancer cells. In allograft models, host PIN1 was critical for normal growth of a subset of pancreatic cancer cell lines that are responsive to HGF signaling. Through the identification of changes to fibroblast activation state and cross-talk following PIN1 loss or inhibition, these data suggest that systemic targeting of PIN1 will suppress the protumorigenic pancreatic ductal adenocarcinoma microenvironment and may differentially affect heterogeneous patient populations. Significance: PIN1 plays a critical role in the response of pancreatic stellate cells to TGFβ and can be targeted to attenuate myofibroblast activation and protumor cross-talk to suppress pancreatic cancer progression.

28 August 2025 in Current Opinion in Physiology
Verified
Journal Article
Open access
VSVidhi M Shah
Vidhi M Shah
RSRosalie C Sears
Rosalie C Sears

3 November 2026
Verified
Other
Open access
YGYifei Guo
Yifei Guo
JFJennifer M. Finan
Jennifer M. Finan
ABAlexandra Bartlett
Alexandra Bartlett
KPKatherine R. Pelz
Katherine R. Pelz
SSShamilene Sivagnanam
Shamilene Sivagnanam
RERobert Eil
Robert Eil
Antibody information for flow cytometry staining

3 November 2026
Verified
Other
Open access
YGYifei Guo
Yifei Guo
JFJennifer M. Finan
Jennifer M. Finan
ABAlexandra Bartlett
Alexandra Bartlett
KPKatherine R. Pelz
Katherine R. Pelz
SSShamilene Sivagnanam
Shamilene Sivagnanam
RERobert Eil
Robert Eil
Antibody information for mIHC staining